Commercial Kardigan targets IPO to support cardiology pipeline progression Pharmaceutical TechnologyKardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline.CardiovascularRead full story pharminent May 27, 2026 (Last updated: May 27, 2026) Pharmaceutical Technology Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA delays verdict on AZ breast cancer drugNext: Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss Related Stories Commercial Moderna builds commercial muscle as new launches loom pharminent June 17, 2026 Commercial ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option pharminent June 8, 2026 Commercial Lilly and Novo face off at ADA 2026 as others seek to compete in obesity pharminent June 5, 2026
